Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 ... (ct candidates. As part of that transact...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002

Date:6/15/2009

ct candidates. As part of that transaction, Alexza licensed to Symphony Allegro its Staccato loxapine program and its Staccato alprazolam program. Since that time, Alexza has been conducting the clinical development of AZ-004 for the acute treatment of agitation, AZ-104 for the acute treatment of migraine headache, and AZ-002 for the treatment of acute panic attacks, with the funds provided by Symphony Allegro.

"In the past 30 months, we have conducted 14 clinical trials with the three product candidates that were licensed into Symphony Allegro. This is a remarkable development achievement, by almost any standard. Moreover, we plan to submit Alexza's first NDA for AZ-004, Staccato loxapine, in the first quarter of 2010. Symphony Capital and RRD International have been a very important part of these accomplishments," said Thomas B. King, Alexza President and CEO. "With the closing of the purchase of Symphony Allegro, we will re-acquire full ownership of AZ-004, AZ-104 and AZ-002. In our partnership with Symphony Allegro, the intended development of these product candidates has been achieved and, assuming our stockholders approve the transaction, Symphony Capital and its investors will be able to share in the future benefits of the advancement of these product candidates."

Mark Kessel, Managing Director of Symphony Capital, added, "We are pleased to have been a part of this collaboration which provided capital and development assistance to enable Alexza to advance these product candidates to the point they are today. The terms of the agreement we have announced today continue to reflect the confidence that we have in Alexza and its management."

Conference Call Information

Alexza will host a conference call tomorrow morning, June 16, 2009, at 9:00 a.m. Eastern Time. A replay of the call will be available for two weeks following the event. The conference call, replay and w
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
2. Alexza and Autoliv Announce Commercial Manufacturing and Supply Agreement for Heat Packages Used in Single-Dose Staccato(R) System
3. Alexzas Corporate Presentation to be Webcast at the Cowen & Company 28th Annual Health Care Conference
4. Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
5. Alexza to Webcast Investor and Analyst Day Presentations
6. Alexzas Corporate Presentation to be Webcast at the Seventh Annual JMP Securities Research Conference and the 2008 Citi Investment Research Global Healthcare Conference
7. Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality
8. Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd.
9. Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
10. Alexza to Announce 2008 Third Quarter Financial Results and Update Its Clinical Pipeline on Thursday, November 6, 2008
11. Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates

Post Your Comments:

[0] Soy Beneficial for Breast Cancer Survivors: Study [1] Researchers Use New Techniques to Assess PTSD [0] Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries)[1] Patient Safety Organization (PSO) Participation: What Every Provider Needs to Know [1] Reportlinker Adds EMR 2010 (Market Analysis, ARRA Incentives, Key Players, and Important Trends)

Other Medicine News:Health News:Time Magazine Reports on Infinitink Tattoo Ink From Nuvilex 2 Health News:Time Magazine Reports on Infinitink Tattoo Ink From Nuvilex 3 Health News:Stigma Keeps Teens From Depression Treatment 2 Health News:The Ottawa Hospital Transforms Procurement and Spend Management with the Oracle(R) E-Business Suite 2 Health News:The Ottawa Hospital Transforms Procurement and Spend Management with the Oracle(R) E-Business Suite 3 Health News:The Ottawa Hospital Transforms Procurement and Spend Management with the Oracle(R) E-Business Suite 4 Health News:Gyminee Raises 525K and Relaunches as DailyBurn 2 Health News:Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking? 2 Health News:Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking? 3 Health News:Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking? 4 Health News:Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking? 5 Health News:Carefx's Newest White Paper Illuminates Healthcare CIOs' Growing Role in Operations, Strategic Thinking and IT Project Decision Making 2 Health News:Carefx's Newest White Paper Illuminates Healthcare CIOs' Growing Role in Operations, Strategic Thinking and IT Project Decision Making 3

Time Magazine Reports on Infinitink Tattoo Ink From Nuvilex Stigma Keeps Teens From Depression Treatment The Ottawa Hospital Transforms Procurement and Spend Management with the Oracle(R) E-Business Suite Gyminee Raises 525K and Relaunches as DailyBurn Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking?Carefx's Newest White Paper Illuminates Healthcare CIOs' Growing Role in Operations, Strategic Thinking and IT Project Decision Making

Breaking Medicine Technology:Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer 2 Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 2 Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 3 Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 4 Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2 Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3 BioMed Realty Trust Completes 24350 Million Financing for Center for Life Science Boston 50338 1 BioMed Realty Trust Completes 24350 Million Financing for Center for Life Science Boston 50338 2 BioMed Realty Trust Completes 24350 Million Financing for Center for Life Science Boston 50338 3 BioMed Realty Trust Completes 24350 Million Financing for Center for Life Science Boston 50338 4 BD Announces Live Webcast of Third Fiscal Quarter Earnings Conference Call 12831 1 Air Traffic Patterns Predict Swine Flu Spread 50335 1 Air Traffic Patterns Predict Swine Flu Spread 50335 2 Air Traffic Patterns Predict Swine Flu Spread 50335 3

[0] Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer [0] Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation [0] Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture

Other Medicine Technology:OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications 2 OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications 3 Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer 2 Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer 3 Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer 4 Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer 5 Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer 6 Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer 7 Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer 8

OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer

Medicine Products:

Digistim 3 Plus Nerve Stimulator MicroStim Nerve Stimulator RDG Nerve Stimulator Ministim® MS-1B Miniature Nerve Stimulator

Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 ...(ct candidates. As part of that transact...),Health